Markets:

Overview

News

Currencies

International

Treasuries

Ocugen, Inc. - Common Stock (NQ:OCGN)

1.330 -0.020 (-1.48%)

Official Closing Price Updated: 4:00 PM EDT, May 22, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Ocugen, Inc. - Common Stock

< Previous 1 2

...

11 12 13 14 15 16 17 18 19

...

36 37 Next >

Why Ocugen Stock Eked Out a Win Today ↗

February 28, 2023

The company is clearly progressing on several fronts with its pipeline programs.

Via The Motley Fool

Ocugen (OCGN) Q4 2022 Earnings Call Transcript ↗

February 28, 2023

OCGN earnings call for the period ending December 31, 2022.

Via The Motley Fool

Why Catalyst Biosciences Shares Are Trading Higher By 105%; Here Are 20 Stocks Moving Premarket ↗

February 28, 2023

Gainers Catalyst Biosciences Inc (NASDAQ: CBIO) rose 105% to $0.49 in pre-market trading. South Korea's GC Biopharma said it has signed an asset purchase agreement with Catalyst Biosciences to acquire...

Via Benzinga

Ocugen Provides Business Update with Fourth Quarter and Full Year 2022 Financial Results

February 28, 2023

From Ocugen

Via GlobeNewswire

More Likely to 5x First: Novavax vs. Ocugen ↗

February 16, 2023

They skyrocketed before. It could happen again.

Via The Motley Fool

1 Reason to Buy Ocugen in 2023 and 2 Reasons to Sell ↗

February 04, 2023

Ocugen has recently broadened its pipeline.

Via The Motley Fool

Ocugen Announces Encouraging Data From Late-Stage COVID-19 Vaccine Study ↗

January 09, 2023

Via Benzinga

Why Shares of Ocugen Jumped Thursday ↗

December 29, 2022

Could short-sellers be enacting a squeeze?

Via The Motley Fool

Earnings Scheduled For February 28, 2023 ↗

February 28, 2023

Companies Reporting Before The Bell • Gaotu Techedu (NYSE:GOTU) is expected to report earnings for its fourth quarter.

Via Benzinga

Ocugen, Inc. Announces Submission of Investigational New Drug Application with U.S. FDA to Initiate a Phase 1 Clinical Trial Evaluating OCU200 for the Treatment of Diabetic Macular Edema

February 27, 2023

From Ocugen

Via GlobeNewswire

Ocugen to Present at Retinal Vascular Disease Drug Development Summit

February 17, 2023

From Ocugen

Via GlobeNewswire

Ocugen to Host Conference Call on Tuesday, February 28 at 8:30 A.M. ET to Discuss Business Updates and Fourth Quarter and Full Year 2022 Financial Results

February 15, 2023

From Ocugen

Via GlobeNewswire

Stocks That Hit 52-Week Lows On Monday ↗

February 13, 2023

On Monday, 42 companies hit new 52-week lows.

Via Benzinga

7 Heavily Shorted Penny Stocks for Your Short-Squeeze Watch List ↗

February 03, 2023

Here are seven heavily shorted penny stocks that can potentially witness a sharp reversal rally in the foreseeable future.

Via InvestorPlace

Ocugen Appoints Quan A. Vu as Chief Business Officer

February 01, 2023

From Ocugen

Via GlobeNewswire

Ocugen, Inc. to Present at 2023 BIO CEO & Investor Conference

January 31, 2023

From Ocugen

Via GlobeNewswire

2 Struggling Stocks to Buy Hand Over Fist in 2023 and 1 to Avoid Like the Plague ↗

January 29, 2023

Two of these stocks have what it takes to rebound and deliver lasting gains.

Via The Motley Fool

Why GeneDx Holdings Shares Are Trading Lower By 8%; Here Are 20 Stocks Moving Premarket ↗

January 27, 2023

Gainers Freightos Limited (NASDAQ: CRGO) shares rose 69.2% to $17.75 in pre-market trading. Freightos listed on the Nasdaq following merger with special purpose acquisition company, Gesher I...

Via Benzinga

3 of the Fastest-Growing Stocks on the Planet in 2023 ↗

January 26, 2023

These hypergrowth stocks are expected to deliver up to 1,075% sales growth this year.

Via The Motley Fool

3 Under-the-Radar Stocks With 590% to 772% Upside in 2023, According to Wall Street ↗

January 23, 2023

Select analysts expect these small-caps stocks to catapult higher in the new year.

Via The Motley Fool

7 ‘Loser’ Stocks to Short for Big Profits ↗

January 11, 2023

These stocks to short can generate significant profits for investors, as they are all tremendously overvalued at this point.

Via InvestorPlace

Exclusive: Top 10 Most Searched Tickers On Benzinga Pro In 2022 — Where Do SPY, Tesla, Apple And AMC Rank? ↗

January 09, 2023

Each trading day features hundreds of headlines and press releases on Benzinga Pro, a leading source for traders to see the latest news on the overall market and individual tickers all in one...

Via Benzinga

Why Is Party City (PRTY) Stock Up 41% Today? ↗

January 09, 2023

Party City (PRTY) stock is in the news Monday as investors prepare for the celebration goods company to file for bankruptcy.

Via InvestorPlace

Why Is Ocugen (OCGN) Stock Up Today? ↗

January 09, 2023

Ocugen is hoping its Indian-made inactivated Covid-19 shot can provide a low-cost boost for those previously given MRNA-based vaccines.

Via InvestorPlace

Tesla's Delivery Wait Times Go Up, China Wants To Secure License For Generic Version Of Pfizer's Paxlovid, India-Made iPhone Exports Surpass $2.5B: Today's Top Stories ↗

January 09, 2023

Bloomberg

Via Benzinga

Ocugen Announces Positive Top-Line Data for COVID-19 Vaccine Candidate COVAXIN™ (BBV152) in Phase 2/3 Immuno-bridging and Broadening Study: Both Co-primary Endpoints Met

January 09, 2023

From Ocugen

Via GlobeNewswire

7 Hot Meme Stocks of 2022 to Sell Before 2023 ↗

December 25, 2022

The value of most of the meme stocks have plunged, but there are still many meme stocks to sell at this point.

Via InvestorPlace

Stocks That Hit 52-Week Lows On Tuesday ↗

December 20, 2022

On Tuesday, 298 companies achieved new lows for the year.

Via Benzinga

Why Is Agrify (AGFY) Stock Down 50% Today? ↗

December 16, 2022

Agrify (AGFY) stock is on the move Friday as the company's shares take a beating after revealing details of a stock offering.

Via InvestorPlace

OCGN Stock Alert: What to Know About Ocugen’s Latest Phase 3 Clinical Trial ↗

December 16, 2022

OCGN stock fell into the red despite Ocugen's success in advancing a regenerative cell therapy product evaluation.

Via InvestorPlace

< Previous 1 2

...

11 12 13 14 15 16 17 18 19

...

36 37 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.